<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479829</url>
  </required_header>
  <id_info>
    <org_study_id>203368</org_study_id>
    <nct_id>NCT01479829</nct_id>
  </id_info>
  <brief_title>Bipolar Depression and Inflammation</brief_title>
  <official_title>Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will attempt to enhance and augment the antidepressant efficacy of a commonly&#xD;
      used antidepressant in poorly responding bipolar depressed patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo-controlled study of patients with bipolar I disorder (BPD) utilizing a&#xD;
      well-known antidepressant, escitalopram (ESC), in combination with the anti-inflammatory&#xD;
      agent, celecoxib (CBX). The investigators hypothesize that combination treatment will lead to&#xD;
      a qualitatively and quantitatively augmented response and will result in greater numbers of&#xD;
      remitters compared to ESC monotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2011</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved affective responses</measure>
    <time_frame>8 weeks</time_frame>
    <description>combined pharmacotherapy of ESC + CBX will result in earlier and/or improved affective responses compared to ESC + placebo measured by rating three levels of assessment of clinical improvement: (a) time of onset of mood response, (b) magnitude of mood response, and (c) prevalence and time point of symptom remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile of combined ESC/CBX therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Determine whether combined pharmacotherapy of ESC + CBX poses safety or tolerability issues, particularly in terms of gastrointestinal bleeding or cardiovascular health over a 8-week course of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>ESC + CBX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram 10 mg twice day plus Celecoxib 200 mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESC + PBO.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Escitalopram 10 mg twice day plus placebo administered twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESC + CBX</intervention_name>
    <description>Escitalopram (ESC) 10 mg twice day given orally twice a day plus Celecoxib (CBX) 200 mg twice daily.</description>
    <arm_group_label>ESC + CBX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESC + PBO.</intervention_name>
    <description>• Escitalopram (ESC) 10 mg twice per day plus Placebo (PBO)administered twice daily.</description>
    <arm_group_label>ESC + PBO.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESC+CBX</intervention_name>
    <description>• Escitalopram 10 mg given twice day plus Celecoxib 200 mg twice daily.</description>
    <arm_group_label>ESC + CBX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 21 - 65 years old at time of screening visit. Both genders and any race will be&#xD;
             accepted.&#xD;
&#xD;
          -  Diagnosis of BPD I or II without significant co-morbid secondary medical or&#xD;
             psychiatric diagnoses; no substance abuse or dependence during preceding 12 months&#xD;
&#xD;
          -  A minimum score of 18 on the first 17 items of the 21-item Hamilton Depression Scale&#xD;
&#xD;
          -  Willingness to washout for a reasonable time (depending on the substance) from:&#xD;
             Vitamin E and fish oils (&gt;600 IU/day), non-aspirin NSAIDs or aspirin (&gt;81 mg/day, H2&#xD;
             receptor antagonists, Ginko biloba, caffeine on morning of blood drawing, and to&#xD;
             institute lights-out at 23:00 hours on the nights before blood drawings&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any abnormal findings on the physical exam, ECG, blood/urine or minor infections&#xD;
&#xD;
          -  Any pre-existing physical pain condition, including fibromyalgia&#xD;
&#xD;
          -  History of peptic ulcer complicated by perforation, hemorrhage, or obstruction;&#xD;
             symptoms of peptic ulcer within 4 weeks of enrollment date&#xD;
&#xD;
          -  Any substance abuse or dependence during the preceding 12 months&#xD;
&#xD;
          -  Clinically significant hypertension, anemia, liver disease, kidney disease, arthritis,&#xD;
             diabetes, recurrent migraines, epilepsy, stroke, gum disease, autoimmune disease&#xD;
&#xD;
          -  Current use of lithium&#xD;
&#xD;
          -  Current use of a stimulant&#xD;
&#xD;
          -  Certain steroids including use of hormonal birth control and any systemic or topical&#xD;
             corticosteroids (hormone replacement therapy will be allowed)&#xD;
&#xD;
          -  Unwillingness to refrain from H2 receptor antagonists, non-aspirin NSAIDs, or aspirin&#xD;
             (mor than 1 mg/day).&#xD;
&#xD;
          -  Use of any anticoagulant agents&#xD;
&#xD;
          -  Use of nicotine-containing substances. Subjects who quit smoking more than 3 months&#xD;
             prior to assessment may be considered for the study&#xD;
&#xD;
          -  Known sensitivity or allergy to the study medications or a need to receive agents that&#xD;
             are contra-indicated in combination with CBX or ESC&#xD;
&#xD;
          -  Unwillingness to fast and abstain from caffeine on mornings of blood drawings&#xD;
&#xD;
          -  A sleep disorder other than insomnia or hypersomnia as a distinct symptom of MDD&#xD;
&#xD;
          -  Inability to commit to the follow-up visits between 8 and 11 am&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Halaris, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola Univeristy Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Angelos Halaris</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar depression</keyword>
  <keyword>Celecoxib</keyword>
  <keyword>Escitalopram</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

